Bagsværd, Denmark, 2 October 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 16 billion to be executed during a 12-month period beginning 2 February 2017.
Under the programme initiated 9 August 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 3.9 billion in the period from 9 August 2017 to 30 October 2017.
Since the announcement as of 25 September 2017, the following transactions have been made under the programme:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 7,499,590 | 2,205,950,196 | |
| 25 September 2017 | 210,000 | 308.05 | 64,691,388 |
| 26 September 2017 | 220,000 | 303.69 | 66,812,522 |
| 27 September 2017 | 210,000 | 302.86 | 63,600,266 |
| 28 September 2017 | 215,000 | 303.85 | 65,328,427 |
| 29 September 2017 | 215,000 | 301.53 | 64,829,174 |
| Accumulated under the programme | 8,569,590 | 2,531,211,974 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 41,621,013 B shares of DKK 0.20, corresponding to 1.7% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 16 billion during a 12-month period beginning 2 February 2017. As of 29 September 2017, Novo Nordisk has repurchased a total of 40,517,561 B shares equal to a transaction value of DKK 10,831,183,966.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
| Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com |
| Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
| Christina Kjær | +45 3079 3009 | cnje@novonordisk.com |
| Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Company announcement No 75 / 2017
